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Abstract  
Background: Although the genetics of asthma has been extensively studied using both 
quantitative and molecular genetic analysis methods, both approaches lack studies specific to 
the childhood phenotype and including other allergic diseases. This study aimed to give 
specific estimates for the heritability of childhood asthma and other allergic diseases, to 
attempt to replicate findings from genome-wide association studies (GWAS) for childhood 
asthma and to test the same variants against other allergic diseases. 
Methods: In a cohort of 25,306 Swedish twins aged 9 or 12, data on asthma were available 
from parental interviews and population-based registers. The interviews also inquired about 
wheeze, hay fever, eczema and food allergy. Through structural equation modeling, the 
heritability of all phenotypes was calculated. A subset of 10,075 twins was genotyped for 16 
single nucleotide polymorphisms (SNPs) selected from previous GWAS; these were first 
tested for association with asthma and significant findings also against the other allergic 
diseases. 
Results: The heritability of any childhood asthma was 0.82 (95% CI 0.79-0.85). For the other 
allergic diseases the range was approximately 0.60-0.80. Associations for six SNPs with 
asthma were replicated, including rs2305480 in the GSDMB gene (OR 0.80, 95% CI 0.74-
0.86, p= 1.5*10-8; other significant associations all below p=3.5*10-4). Of these, only 
rs3771180 in IL1RL1 was associated with any other allergic disease (for hay fever, OR 0.64, 
95%CI 0.53-0.77, p=2.5*10-6). 
Conclusion: Asthma and allergic diseases of childhood are highly heritable, and these high-
risk genetic variants associated specifically with childhood asthma, except for one SNP shared 
with hay fever. 
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Introduction 
Asthma is a complex, prevalent, and highly heritable disease (1). It affects children as well as 
adults and is often comorbid with other allergic diseases such as hay fever and atopic eczema 
(2, 3). Previous studies of the genetic effects behind asthma have applied a variety of different 
definitions of the disease and study populations often include both children and adults. 
However, asthma is expressed differently in different age groups (4) and features substantial 
heterogeneity of phenotypes even within childhood asthma and wheeze (5).    
The underlying genetic components of asthma have been demonstrated using quantitative (6-
11) as well as molecular genetic methods (12-14). While these principally intend to describe 
the same phenomenon the perspectives are somewhat different. Quantitative genetic methods 
estimate the degree to which genes are responsible for the variation of a trait or disease within 
a population–the heritability – but cannot say which specific genes are involved. Molecular 
genetics identifies these genetic variants – often specific single nucleotide polymorphisms, 
SNPs – yet most commonly used methods (including genome-wide association studies, 
GWAS) do not capture the full extent of human genetic variation.  
Twin models are frequently applied to estimate the magnitude of genetic effects, using 
correlations of a disease or trait within monozygotic (MZ) and dizygotic (DZ) twins and an 
assumption of shared segregating genes (100% within MZ and on average 50% within DZ 
pairs) to estimate the heritability of the disease (15). In the past, the heritability of asthma was 
estimated to be between 50 and 90% (2, 6-11, 16-22). However, it is difficult to draw reliable 
conclusions regarding asthma in children based on these studies, as some concern only adults 
(8, 9, 17, 18, 20) and the study populations with child subjects often include also adolescents 
and young adults (6, 17, 21) or address only preschool years (7, 19, 22). The few studies that 
focus on mid childhood to early adolescence (2, 10, 11) are comparably small. Further, 
previous research has suggested that patterns of variance components, including heritability, 
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of asthma may change over time (21). The heritability of allergic and otherwise related 
phenotypes is less studied, though reported estimates for hay fever (2, 8, 10, 16, 20, 22, 23) 
and eczema (2, 20, 22) lie in the same approximate range; although as many of these 
estimates are from the same studies cited previously, similar selection issues exist. 
In the recent decade GWAS gained tremendous popularity in molecular genetic studies of 
complex traits, and typically examine hundreds of thousands of variants in the search for loci 
associated with various phenotypes. The most notable asthma GWAS have been carried out 
by the GABRIEL (12) and EVE (13) consortia, respectively. These and other GWAS (14, 24-
26) and genetic association studies of candidate genes/ regions (27, 28) found several high 
risk alleles strongly associated with childhood asthma. In particular variants in genes on 
chromosomes 2, 5, 6 and 17 replicate between studies. Due to the nature of meta- and pooled 
analyses, heterogeneity in methodology is inevitable, and usually very general asthma 
phenotypes have been defined.  
Thus, quantitative and molecular genetic methods agree that there are underlying genetic 
effects behind asthma, but both approaches have suffered from variability in phenotype 
definitions and study population. Because of this current knowledge is not necessarily 
applicable or specific to childhood asthma. In addition, the methods aim to explain the genetic 
effects from different perspectives. By the application of both quantitative and molecular 
genetic methods within a single study population, where subject characteristics and phenotype 
definitions align, unique inferences regarding the genetic effects of childhood asthma and 
allergic diseases may be made. 
The dual aim of this study is to provide new heritability estimates for childhood asthma and 
related phenotypes within a large cohort of Swedish twins, and to test if a selection of SNPs 
found to be of importance for childhood asthma are also associated with the related 
phenotypes.
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Materials and methods 
CATSS-9/12 
The Child and Adolescent Twin Study in Sweden (CATSS) is a cohort of twins born in and 
residents of Sweden on their 9th (and, during the first three years of data collection, 12th) 
birthday. Parents were interviewed over telephone regarding the twins’ health and other 
characteristics (29). Data collection is still ongoing; so far including over 25,000 twins. The 
current study included interview data from all participating twins as of October 2014.  
The interview contains questions regarding physical similarities between the twins; based on 
these an algorithm to determine their zygosity with more than 95% accuracy has been 
constructed (30). Starting in 2008, DNA extracted from saliva samples collected following the 
CATSS interview was tested using a 46-SNP-array to confirm zygosity (31). When available, 
DNA-based zygosity assessment took precedence. Overall, 58% (n=14,608) of the study 
participants had their zygosity assessed by algorithm and 41% (n=10,398) by DNA. The 
CATSS-9/12 study was approved by the Regional Ethical Review Board of Stockholm, 
Sweden.  
Cohorts  
The full CATSS cohort consisted of 25,306 twins from 12,635 pairs. All complete same-sex 
MZ and DZ pairs of the full cohort were included in main heritability analyses. Twins with 
available saliva samples and where DNA extraction yielded a sufficient amount of DNA were 
potential targets for genotyping. In DZ pairs both twins were genotyped whereas in MZ pairs 
only one twin was genotyped, and SNP-data were imputed for the co-twin. Genotype data was 
available for 12,388 (49% of the full CATSS cohort) twins. Of these, 8,618 (70%) had 
zygosity confirmed by DNA, 3,521 (28%) were opposite-sex DZ twins for which 
confirmation by DNA is unnecessary, and 249 (2%) were assessed by algorithm. Twins of 
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unknown zygosity (n=35) were treated as DZ in genetic association analysis. One MZ twin of 
each pair was randomly selected for genetic association analyses. A total of 10,075 twins 
remained. Out of 2,314 MZ twins randomly selected, 1,356 (59%) had own genotype data. 
The relationship between subgroups of the cohort is illustrated in Supporting information, 
Figure 1. 
Phenotype definitions 
Asthma was defined from interview- and register-based data. The CATSS-9/12 question “Has 
your child ever had asthma?” was used to define ever asthma.   
Additional asthma outcomes extracted from national population-based health registers were 
previously validated against medical records.(32) Asthma medication was defined as either 1) 
>2 dispenses of inhaled corticosteroids, ICS (ATC code R03BA), fixed combinations of β2-
adrenoreceptor agonists and ICS, β2-ICS (R03AK) and/or leukotriene receptor antagonists, 
LTRA (R03DC), independent of time between distributions or 2) >3 dispenses of ICS, 
selective β2-adrenoreceptor agonists, β2 (ATC code R03AC), β2-ICS and/or LTRA within a 
year, registered in the Prescribed Drug Register (PDR) between 4.5 and 18 years of age. 
Register-based asthma diagnosis in the National Patient Register (NPR) was defined by 
primary ICD-10 diagnosis J45 or J46 or ICD-9 493. The phenotype any asthma was defined 
as presence of any of the aforementioned asthma phenotypes. If asthma ever was missing and 
there were no reports of asthma medication or register-based asthma diagnosis, any asthma 
was set to missing.  
All related phenotypes were defined based on parental reports in the CATSS-9/12 telephone 
interview. Wheezing ever was defined as yes to the question “Has your child ever had whistle 
breathing?”. This question was only presented to parents who had not already reported that 
their child had asthma. Wheezing after 3 years of age was the subgroup of ever wheezers with 
symptoms after a pre-defined age cutoff. Hay fever, food allergy and atopic eczema ever were 
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all defined based on the parental telephone interview. I -in the case of eczema, the question 
was for eczema ever with a follow-up on the specific subtype(s) (33). 
Genotyping 
In total 18 single nucleotide polymorphisms (SNPs) previously associated with childhood 
asthma (12, 13, 27), in addition to two SNPs associated with adult asthma (12) or serum IgE 
levels (34) were selected for genotyping. The selected SNPs represented the IL6R, IL1RL1, 
IL18R1, TSLP, SLC22A5, IL13, HLA-DQ, IL33, RORA, SMAD3, Z2BP2, GSMB, GSDMA 
and IL2RB genes; the location of successfully genotyped SNPs in relation to the genes (in 
intron, exon, or nearby region) are presented in Table 3. DNA was extracted from saliva 
samples using the Oragene® DNA self-collection kit (DNA Genotek, Inc. Ottawa, ON, 
Canada). Genotyping was conducted using KASP(ar) PCR SNP genotyping system 
(KBioscience, Hoddesdon, Herts, UK). Two of the originally selected polymorphisms 
(rs9273349 and rs9469220, both located on chromosome 6 in the HLA-DQ region) could not 
be successfully genotyped within the population. Besides these, genotyping success rate was 
>95%. Individuals with unsuccessful genotyping of more than 3 of the remaining 16 SNPs 
(n=415) were excluded from genetic association analyses. Following these exclusions, 9,660 
individuals remained. Of these, 2,257 (23.4%) were MZ, 7,375 (76.3%) were DZ (of which 
4,040 were from same-sex and 3,335 from opposite-sex pairs) and 28 (0.3%) were of 
unknown zygosity. All SNPs were found to be in Hardy-Weinberg equilibrium. Some of the 
SNPs were highly correlated in the data (r2 above 0.85); r2 between rs2305480 and 
rs11078927 was 0.99 and 0.91 between rs12936231 and rs726389. 
Statistical analysis 
Prevalences of all the phenotypes were estimated in the full CATSS cohort, as well as in the 
groups included in heritability and genetic association analyses, respectively. 
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Heritability 
Twin model analyses were conducted in the R-package OpenMX, an open source structural 
equation modeling solution (35). Univariate liability threshold models were specified using 
either an ACE or ADE structural equation.  The standardized variance components A 
(additive genetics), E (nonshared environment) and either C (common environment) or D 
(genetic dominance, accounting for part of the genetic effect) were estimated with 95% CI. 
Model selection was based on comparison of phenotype-specific tetrachoric correlations 
between MZ and DZ twins; an ADE model was selected if the tetrachoric correlation in DZ-
same sex (DZ-ss) pairs was less than half of that in MZ pairs. For MZ pairs, the A and D (if 
applicable) factors are fully correlated; r in DZ pairs there is a 50% correlation for A and 25% 
for D. The sum of the variance components is standardized to 1, i.e. the combined effects of 
A, C and D, or E are the total variance of the disease or trait within the population. Likelihood 
ratio tests (LRTs) were used to compare AE models to full ACE or ADE models. When C or 
D could be dropped without significant reduction in fit of the model, the AE model was 
interpreted. Additional sex-limitation models included opposite-sex dizygotic (DZ-os) twins, 
allowing for either quantitative (the same genes are involved between sexes but effects vary in 
size; separate estimates of each variance component are needed) or qualitative (different 
genes are involved for males and females; the variance component A differs by a factor rA) 
differences in A by sex. LRTs of these models compared to models without and including 
both parameters were performed. Estimates were presented when relevant.  
Genetic association 
Genetic association analyses were performed in PLINK (36) v.1.08 using the –logistic 
command, based on allele frequencies and using the minor allele as the risk allele. The –
within command was used to account for clustering within DZ twin pairs through producing 
robust standard errors using the Huber-White (37) To account for multiple testing, a p-value 
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below 3.5*10-4 (calculated based on Bonferroni correction for 9 phenotypes and 16 SNPs - 
144 tests - with an alpha level of 0.05) was required for an observed effect to be deemed 
statistically significant. Genetic association analysis was carried out in two steps. All SNPs 
were tested for possible association with any asthma; then only SNPs significantly associated 
with any asthma were tested for association with the other asthma and related phenotypes. 
Due to the nature of these data, commonly used methods for calculating a cumulative 
percentage of the variance explained by the SNPs could not be used. Instead, the joint 
predictive value of significantly associated SNPs with regard to any asthma was examined by 
fitting a logistic regression model in Stata 13 including the risk alleles as covariates. Then, 
McFadden’s pseudo-R2 was computed in postestimation, the resulting value constituting a 
marker of the fit of a model with all the risk alleles included compared to one without. A 
small estimate indicates low total variance explained (38).  
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Results  
Table 1 shows descriptive characteristics and phenotype prevalences for the full CATSS 
cohort, as well as for the subgroups included in the heritability (ACE/ADE models) and 
genetic association analyses, respectively. In the full cohort, 19.6% (n=4,956) had any 
asthma, 14.5% (n=3,663) had wheezing ever, and the prevalences of hay fever, food allergy 
and atopic eczema ever were 7.8 (n=1,969), 8.3 (n=2,105) and 13.1% (n=3,314) respectively. 
Tetrachoric correlations within MZ and DZ twin pairs for the different phenotypes are 
displayed in Table 2. Based on these correlations, ADE models were selected for asthma ever, 
asthma medication, hay fever ever and atopic eczema ever. For all other phenotypes ACE 
models were fitted. Based on LRTs there was no significant improvement in the model fit of 
the ACE/ADE models compared to the simpler AE models for any phenotypes except 
register-based asthma diagnosis and wheezing after three years of age.  
There were statistically significant additive genetic (A) components for all asthma 
phenotypes, with estimates ranging from 0.73 (asthma medication, 95% CI 0.68-0.78) to 0.83 
(register-based asthma diagnosis, 95% CI 0.79-0.86), as well as for the related phenotypes, 
where the highest estimate was 0.78 (95% CI  0.74-0.82) for food allergy. Genetic dominance 
(D) was statistically significant in atopic eczema ever, where the estimate for the D 
component was 0.28, 95% CI 0.03-0.54. Only register-based asthma diagnosis (C 0.19, 95% 
CI 0.07-0.31) and wheezing after three years of age (C 0.18, 95% CI 0.02-0.33) had a 
statistically significant C component. The non-shared environment (E) ranged between 0.13 
(asthma ever, 95% CI 0.11-0.16) and 0.27 (asthma medication, 95% CI 0.22-0.32).  
Sex limitation models revealed some minor quantitative and qualitative differences in 
heritability between males and females for asthma. Sex-specific heritability estimates for the 
relevant asthma phenotypes are presented in Supporting information, Table S1.  
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Of the 16 tested SNPs in the first step of genetic association analysis, six were significantly 
associated with any asthma based on p-values below 3.5*10-4 (Table 3). These were 
rs3771180 in the IL1RL1 gene on Chromosome 2 (p= 1.0*10-5, OR 0.76, 95%CI 0.68-0.86,), 
and from Chromosome 17 rs12936231 in the Z2BP2 gene (p =1.5*10-7, OR 1.23, 95%CI 
1.14-1.33), rs2305480 (p = 1.5*10-8 , OR 0.80, 95%CI 0.74-0.86), rs11078927 (p=1.6*10-8, 
OR 0.80, 95%CI 0.75-0.86) and rs7216389 (p=2.0*10-7, OR 1.23, 95%CI 1.14-1.33) in the 
GSDMB gene, and rs3894194 in the GSDMA gene (p=1.0*10-5, OR 1.20, 95%CI 1.10-1.29). 
McFadden’s pseudo-R2 using the significantly associated SNPs was 0.008, indicating that the 
total predictive value of these genetic variants with regard to any asthma was very low.  
When the six SNPs associated with any asthma were further investigated in relation to other 
asthma and related phenotypes, all were significantly associated with asthma ever (Table 4).  
Beyond this, the majority of SNPs located on Chromosome 17 were significantly associated 
with register-based asthma diagnosis and asthma medication. The only SNP associated with 
any of the related phenotypes was rs3771180 with hay fever ever (Table 4).   
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Discussion 
We studied genetic effects underlying several childhood phenotypes using a combination of 
quantitative genetic and molecular methods, and saw significant additive genetic effects for 
asthma and related diseases. Genetic effects were strongest for asthma. Wheezing was among 
the phenotypes where the effect of genetics was less pronounced. We also confirmed some of 
the variants previously associated with childhood asthma from GWAS, although, as expected, 
the predictive value of these SNPs was very low. The SNPs were primarily associated with 
asthma and did not overlap with any of the related phenotypes save for hay fever, as 
rs3771180 in IL1RL1 was associated with both. 
The magnitude of the additive genetic (A) components for asthma in our study was in line 
with previous studies including children (2, 6, 7, 10, 11, 17, 19, 22). However, the overall 
pattern of variance components in asthma differs between studies. We saw no significant 
variability due to shared environment (C) except for register-based asthma diagnosis. This is 
in agreement with some (2, 10, 17, 19, 22), but not all (6, 7) previous studies involving 
children. One study of a particularly young population (3 years and below) showed a large 
contribution of shared environment to phenotypes similar to ours (diagnosis, medication use 
and hospitalization), indicating that shared environment may be more important at younger 
ages (7).  
The SNPs in our material significantly associated with any asthma included the top two 
findings for childhood asthma from the GABRIEL consortium (rs2305480 and rs3894194) - 
one of few GWAS to report estimates separately for childhood asthma. (12)  A later study 
confirmed association of rs2305480 and rs11078927 with asthma diagnosis, bronchial hyper-
reactivity and asthma severity (39), providing support that genetic variation in this position is 
biologically and clinically relevant.   
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Studies on correlations of asthma, hay fever and eczema within relatives have confirmed that 
there is large comorbidity and shared additive genetic components in adult (16, 18) and child 
populations (22, 28), and some GWAS have found loci shared by asthma and atopy (40-42). 
As we tested a limited number of SNPs our results cannot be used to draw extensive 
conclusions on genetic variants shared between asthma and related phenotypes, 
sincecomorbidity between diseases was not used as an outcome in this study.  
 We could not replicate all the previously genetic associations in our material, including 
rs744910 in SMAD3. One possible explanation is lack of statistical power. Assuming a 
phenotype prevalence of 10% and a risk allele frequency of 0.40, we had 76-99% power to 
detect an OR of 1.20-1.30. These ORs are based on previous literature, and the power 
presented to detect a statistically significant effect in a material of our size with a desired 
alpha level of 3.5*10-4 (44). Considering the actual allele frequencies in this study, the power 
to confirm previous associations in our material was likely slightly greater. Another potential 
explanation for non-replication is that these variants, originally identified in GWAS with 
pooled data from cohorts of diverse origin, may be less important in a more homogenous 
Swedish population. More studies within populations  similar to ours would be required to 
confirm this. 
 
This is one of the largest studies on heritability of asthma and related allergic diseases in 
children, providing more robust estimates for many of the phenotypes than were previously 
available. To our knowledge this is the first study providing an estimate specifically for the 
heritability of childhood wheeze; previous studies have only included adults (8, 16, 20). The 
presence of a large, population-based twin cohort assured a representative sample within a 
highly relevant age range. Information on several phenotypes from questionnaires as well as 
registers gives us a unique opportunity to draw multifaceted conclusions regarding these 
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prevalent causes of childhood morbidity. It is sometimes suggested results from twin studies 
would be less generalisable to the remaining population, but we have recently shown this is 
not a major concern (43).  The register-based asthma outcomes we applied were originally 
validated based on medical records using clinical criteria, with high predictive values for 
clinically relevant pediatric asthma (32). 
Results from twin models should be interpreted in the light of their assumptions and 
limitations These include the equal environment assumption (MZ and DZ twins are assumed 
to have the same degree of shared environment), an absence of gene-environment interaction, 
and that the specific underlying mechanisms involved in each component (A, C or D, and E) 
are not identified. In addition, in this study, there could also be a potential effect of rater bias 
for the parent-reported outcomes. A limitation of our definition of wheezing is that the 
question was only posed to parents who had not already answered “yes” to the question about 
asthma ever. This represents therefore a particular subtype of wheeze—one which has not, by 
the age of 9 or 12, become or at least not been acknowledged as asthma. Such wheezing may 
be due to different underlying biological mechanisms and thus interesting in its own right; 
however, this difference between our definition of wheeze as compared to previous studies 
should be taken into account. It is possible to identify eczema medication use through 
Swedish registers (45) but we did not have access to a validated medication proxy for eczema, 
and direct clinical measures such as FeNO or lung function were not available for this 
population. 
Through the use of a combination of twin methodology and molecular genetics, this study 
confirms underlying additive genetic effects behind asthma and related phenotypes in mid 
childhood. We were able to replicate previously strong associations between variants at the 
ORMDL3 and IL1RL1 regions and asthma across several different definitions. These genetic 
variants appeared to be specific to asthma with the exception of one SNP that was also 
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associated with hay fever. Our findings support these highly correlated SNPs remain as 
suitable targets for the study of genetic variation in relation to epidemiological and clinical 
studies of asthma. 
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Table 1 Background characteristics of the study population and phenotype prevalences as distributed in the subgroups within the study; the full 
cohort, those selected for ACE/ADE models, those with genotype data available and finally those randomly selected from this group for genetic 
association analysis (removing one MZ twin from each MZ pair). 
 Full CATSS cohort 
N (%) 
Selected for ACE / ADE 
models  
N (%) 
Genotype data available 
 N (%) 
Randomly selected for 
genetic association 
analysis  
N (%) 
All 25,306 (100) 15,896 (100) 12,388 (100) 10,075 (100) 
Characteristics     
Gender     
 Male 12,867 (50.9) 8,168 (51.4) 6,196 (50.0) 5,104 (50.7) 
 Female 12,439  (49.1) 7,728 (48.6) 6,192 (50.0) 4,971 (49.3) 
Age at telephone interview, years     
 9 18,786 (74.2) 11,546 (72.6) 9,674 (70.0) 7,121 (70.7) 
 12 6,520 (25.8) 4,350 (27.4) 3,714 (30.0) 2,954 (29.3) 
Zygosity     
 MZ 7,042 (27.8) 7,042 (44.3) 4,627 (37.4) 2,314 (23.0) 
 DZ-same sex 8,854 (35.0) 8,854 (55.7) 4,205 (34.0) 4,205 (41.7) 
 DZ-opposite sex 8,834 (34.9) - 3,521 (28.4) 3,521 (35.0) 
 Unknown 576 (2.3) - 35 (0.3) 35 (0.3) 
Asthma     
Interview-based     
Asthma ever     
 Yes 3,519 (13.9) 2,181 (13.7) 1,725 (13.9) 1,416 (14.1) 
 No 21,582 (85.3) 13,584 (85.5) 10,579 (85.4) 8,592 (85.3) 
 Missing 205 (0.8) 131 (0.8) 84 (0.7) 65 (0.7) 
Register-based     
Asthma medication      
 Yes 2,479 (9.8) 1,507 (9.5) 1,304 (10.5) 1,102 (10.9) 
 No 22,827 (90.2) 14,389 (90.5) 11,084 (89.5) 8,973 (89.1) 
Asthma diagnosis      
 Yes 2,743 (10.8) 1,710 (10.8) 1,402 (11.3) 1,169 (11.6) 
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 No 22,563 (89.2) 14,186 (89.2) 10,986 (88.7) 8,906 (88.4) 
Any asthma (interview or register)     
 Yes 4,956 (19.6) 3,056 (19.2) 2,493 (20.1) 2,061 (20.5) 
 No 20,217 (79.9) 12,757 (80.3) 9,845 (79.5) 7,975 (79.2) 
 Missing1 133 (0.5) 83 (0.5) 50 (0.4) 39 (0.4) 
Related phenotypes (interview)     
Wheezing ever     
 Yes 3,663 (14.5) 2,336 (14.7) 1,838 (14.8) 1,479 (14.7) 
 No 17,978 (71.0) 11,290 (71.0) 8,770 (70.8) 7,129 (70.8) 
 Missing 3,665 (14.5) 2,270 (14.3) 1,780 (14.4) 1,467 (14.6) 
Wheezing after 3 years of age     
 Yes 1,962 (7.8) 1,223 (7.7) 967 (7.8) 790 (7.8) 
 No 19,173 (75.8) 12,065 (75.9) 9,352 (75.5) 7,593 (75.4) 
 Missing 4,171 (16.5) 2,608 (16.4) 2,069 (16.7) 1,692 (16.8) 
Hay fever ever     
 Yes 1,969 (7.8) 1,234 (7.8) 990 (8.0) 813 (8.1) 
 No 23,050 (91.1) 14,473 (91.1) 11,278 (91.0) 9,157 (90.1) 
 Missing 287 (1.1) 189 (1.2) 120 (1.0) 105 (1.0) 
Food allergy ever     
 Yes 2,105 (8.3) 1,315 (8.3) 1,023 (8.3) 828 (8.2) 
 No 23,010 (90.9) 14,473 (91.1) 11,276 (91.0) 9,177 (91.1) 
 Missing 191 (0.8) 108 (0.7) 89 (0.7) 70 (0.7) 
Atopic eczema ever     
 Yes 3,314 (13.1) 2,093 (13.2) 1,769 (14.3) 1,428 (14.2) 
 No 21,848 (86.3) 13,712 (86.3) 10,554 (85.2) 8,602 (85.4) 
 Missing 144 (0.6) 91 (0.6) 65 (0.5) 45 (0.5) 
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Table 2 Tetrachoric correlations and twin models for asthma and related phenotypes using full MZ and same-sex DZ twin pairs from CATSS-
9/12 (n=15,896) 
 
     Variance component estimate (95% CI) Fit of model 
 N (%) rMZ rDZ-ss Model A C or D E -2lnL P-value* 
Total 15,896 (100)         
Asthma          
Interview-based          
Asthma ever 2,181 (13.7) 0.87 0.42 ADE 0.79 (0.55-0.89) 0.08 (0.00-0.33) 0.13 (0.10-0.16) 11543.67 0.50 AE 0.87 (0.84-0.89) - 0.13 (0.11-0.16) 11544.12 
Register-based          
Asthma medication  1,507 (9.5) 0.74 0.32 ADE 0.51 (0.22-0.76) 0.23 (0.00-0.54) 0.25 (0.21-0.31) 9505.79 0.12 AE 0.73 (0.68-0.78) - 0.27 (0.22-0.32) 9508.17 
Asthma diagnosis 1,710 (10.8) 0.81 0.51 ACE 0.62 (0.48-0.76) 0.19 (0.07-0.31) 0.19 (0.15-0.23) 10033.95 <0.01 AE 0.83 (0.79-0.86) - 0.17 (0.14-0.21) 10043.39 
Any asthma 
(interview or 
register) 
3,056 (19.2) 0.81 0.45 
ACE 0.73 (0.61-0.84) 0.09 (0.00-0.19) 0.19 (0.16-0.22) 14351.11 
0.10 AE 0.82 (0.79-0.85) - 0.18 (0.15-0.21) 14353.82 
Related phenotypes       -     
Wheezing ever 2,336  (14.7) 0.75 0.44 
ACE 0.63 (0.49-0.78) 0.12 (0.00-0.24) 0.25 (0.21-0.29) 11791.01 
0.07 
AE 0.76 (0.72-0.80) - 0.24 (0.20-0.28) 11794.18 
Wheezing after 3 
years of age 1,223 (7.7) 0.77 0.49 
ACE 0.60 (0.42-0.78) 0.18 (0.02-0.33) 0.22 (0.17-0.28) 7698.00 
0.03 
AE 0.80 (0.75-0.84) - 0.20 (0.16-0.25) 7702.98 
Hay fever ever 1,234 (7.8) 0.78 0.39 ADE 0.78 (0.48-0.82) 0.00 (0.00-0.31) 0.22 (0.18-0.27) 8108.884 0.99 AE 0.78 (0.73-0.82) - 0.22 (0.18-0.27) 8108.884 
Food allergy ever 1,315 (8.3) 0.78 0.40 ACE 0.75 (0.57-0.82) 0.03 (0.00-0.19) 0.22 (0.18-0.27) 8492.27 0.67 
AE 0.78 (0.74-0.82) - 0.22 (0.18-0.26) 8492.45 
Atopic eczema ever 2,093 (13.2) 0.83 0.35 ADE 0.56 (0.30-0.81) 0.28 (0.03-0.54) 0.16 (0.13-0.19) 11436.76 0.03 
AE 0.83 (0.80-0.86) - 0.17 (0.14-0.20) 11441.51 
 
Notes: 
* P-value for likelihood ratio test comparing the null model (AE) to the alternate model (ACE or ADE). A significant result in the likelihood ratio test means the alternate 
model has a better fit to the data. 
Abbreviations:  
-2lnL: minus twice the log likelihood  
A: additive genetic component 
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C: shared environment component 
D: genetic dominance component 
E: unique environment component 
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Table 3 Association of the successfully genotyped SNPs with any asthma in genotyped twins and (one randomly selected MZ twin per pair), 
Eexcluding individuals with missing data on more than 3 SNPs, n=415, after which n=9,660 individuals remained. Of these, 2,257 (23.4%) were 
MZ, 7,375 (76.3%) were DZ and 28 (0.3%) were of unknown zygosity. Controls are unaffected by all other phenotypes (including within same 
“group” of phenotypes) 
 
CHR Gene Location SNP Minor allele MAF in cases MAF in controls P OR (95% CI) 
1 IL6R Intron rs4129267 T 0.39 0.39 0.55 1.02 (0.95 - 1.11) 
2 IL1RL1 Intron rs3771180 T 0.11 0.14 1.0 * 10-5 0.76 (0.68 - 0.86) 
2 IL18R1 Intron rs3771166 A 0.36 0.37 0.64 0.98 (0.91 - 1.06) 
5 TSLP Nearby region rs1837253 T 0.27 0.27 0.58 0.98 (0.89 - 1.07) 
5 SLC22A5 Intron rs2073643 T 0.50 0.49 0.10 1.07 (0.99 - 1.15) 
5 IL13 Intron rs1295686 T 0.22 0.21 0.15 1.07 (0.98 - 1.18) 
9 IL33 Nearby region rs1342326 C 0.16 0.14 0.02 1.14 (1.02 - 1.26) 
9 IL33 Nearby region rs2381416 C 0.26 0.24 0.04 1.10 (1.00 - 1.20) 
15 RORA Intron rs11071559 T 0.12 0.13 0.09 0.90 (0.80 - 1.02) 
15 SMAD3 Intron rs744910 A 0.50 0.49 0.86 1.01 (0.93 - 1.09) 
17 Z2BP2 Intron rs12936231 C 0.52 0.47 1.5 * 10-7 1.23 (1.14 - 1.33) 
17 GSDMB Exon rs2305480 A 0.42 0.47 1.5 * 10-8 0.80 (0.74 - 0.86) 
17 GSDMB Intron rs11078927 T 0.42 0.47 1.6 * 10-8 0.80 (0.74 - 0.86) 
17 GSDMB Intron rs7216389 T 0.53 0.47 2.0 * 10-7 1.23 (1.14 - 1.33) 
17 GSDMA Exon rs3894194 A 0.50 0.45 1.0 * 10-5 1.20 (1.10 - 1.29) 
22 IL2RB Intron rs2284033 A 0.44 0.45 0.10 0.94 (0.87 - 1.01) 
 
CHR: Chromosome 
SNP: Single nucleotide polymorphism 
MAF: Minor allele frequency 
L95 and U95: Lower and upper bound of the 95% confidence interval of the odds ratio 
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Table 4 Association of the six SNPs most strongly associated with any asthma with all other phenotypes in the first half of the twin data, 
excluding individuals with missing data on more than 3 SNPs, n=415, after which n=9,660 individuals remained. Of these, 2,257 (23.4%) were 
MZ, 7,375 (76.3%) were DZ and 28 (0.3%) were of unknown zygosity.  Controls are unaffected by all other phenotypes (including within same 
“group” of phenotypes)-. 
 
rs3771180 rs12936231 rs2305480 rs11078927 rs7216389 rs3894194 
Phenotype OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Asthma ever 0.73 (0.63-0.84) 1.5*10-5 1.27 (1.17-1.40) 1.3*10-7 0.76 (0.70-0.83) 2.8*10-9 0.76 (0.70-0.83) 3.9*10-9 1.29 (1.18-1.41) 5.1*10-8 1.31 (1.19-1.43) 9.8*10-9 
Asthma 
medication 0.81 (0.70-0.94) 6.6*10
-3 1.24 (1.12-1.38) 2.5*10-5 0.80 (0.73-0.89) 1.3*10-5 0.80 (0.73-0.88) 1.8*10-5 1.22 (1.10-1.35) 9.9*10-5 1.17 (1.06-1.28) 3.3*10-3 
Register-based 
asthma 
diagnosis 
0.78 (0.67-0.90) 1.1*10-3 1.24 (1.13-1.37) 1.1*10-5 0.78 (0.71-0.86) 8.8*10-7 0.78 (0.71-0.86) 1.0*10-6 1.25 (1.14-1.38) 6.0*10-6 1.19 (1.08-1.31) 5.7*10-4 
Wheezing ever 0.97 (0.86-1.10) 0.61 1.02 (0.94-1.11) 0.65 0.95 (0.87-1.04) 0.25 0.95 (0.87-1.43) 0.24 1.01 (0.93-1.10) 0.79 1.00 (0.91-1.09) 0.95 
Wheezing after 
3 years of age 0.96 (0.82-1.12) 0.60 1.04 (0.93-1.16) 0.54 0.92 (0.83-1.03) 0.16 0.92 (0.83-1.04) 0.17 1.00 (0.90-1.12) 0.94 0.99 (0.89-1.11) 0.90 
Hay fever ever 0.64 (0.53-0.77) 2.5*10-6 1.10 (0.99-1.23) 0.10 0.89 (0.80-0.99) 0.04 0.89 (0.80-0.99) 0.04 1.10 (0.98-1.23) 0.11 1.14 (1.23-1.28) 0.02 
Food allergy 
ever 0.89 (0.76-1.05) 0.17 1.12 (1.00-1.25) 0.06 0.89 (0.80-0.99) 0.03 0.88 (0.79-0.99) 0.03 1.12 (1.00-1.25) 0.04 1.12 (1.00-1.25) 0.05 
Atopic eczema 
ever 0.92 (0.81-1.05) 0.21 1.01 (0.93-1.10) 0.82 0.96 (0.88-1.05) 0.42 0.96 (0.88-1.05) 0.38 1.04 (0.95-1.13) 0.44 1.07 (0.98-1.17) 0.14 
 
  
 
 
 
 
 
